Technology areas: Biotechnology & Pharmaceuticals • Transportation, E-Commerce & Mechanical Systems
9 pending office actions • 7 clients • 9 examiners • 9 art units • 0 of 9 (0%) have an AI response strategy ready
Parker Poe Adams & Bernstein, LLP handles Biotechnology & Pharmaceuticals matters across 238 career applications. The profile records 9 pending office actions, indicating active prosecution within the reported portfolio.
The resolved allowance rate is 80.43%, and allowed matters receive an average of 4.26 office actions. These figures show both the reported resolution outcome and the examination activity associated with allowance. Practitioners can use them to assess response workload and to frame expectations for claim prosecution in this technology area.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 5 (56%) |
| §102 only | 1 (11%) |
| Double-patenting + other | 1 (11%) |
| Multi-statute (no §101) | 2 (22%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HSIAO, JAMES K | 1 | 77.1% | +15.2% |
| KRISHNAN, GANAPATHY | 1 | 52.7% | +1.3% |
| NIEBAUER, RONALD T | 1 | 40.8% | +34.0% |
| EMMETT, MADISON B | 1 | 80.3% | +9.9% |
| CHANG, KYUNG SOOK | 1 | 60.5% | +40.8% |
| PURDY, KYLE A | 1 | 41.0% | +35.7% |
| MOU, LIYUAN | 1 | 43.8% | +59.9% |
| HALL, ZACHARY A | 1 | 61.6% | +49.4% |
| KLEIN, GABRIEL J | 1 | 66.1% | +24.4% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18692460 | DENTAL IMAGING SYSTEM, AND DENTAL ROBOT SYSTEM INCLUDING SAME | EMMETT, MADISON B | 8d |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18896412 | DAMPING APPARATUS | HSIAO, JAMES K | — |
| 18294314 | NOVEL CATIONIC LIPID COMPOUNDS | PURDY, KYLE A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18692208 | ACTIVE INGREDIENT DELIVERY SYSTEM | CHANG, KYUNG SOOK | 70d |
| 18896412 | DAMPING APPARATUS | HSIAO, JAMES K | — |
| 18699969 | NOVEL DEUTERATED CYANO COMPOUNDS, PREPARATION METHODS, COMPOSITIONS AND APPLICATIONS | NIEBAUER, RONALD T | — |
| 18294314 | NOVEL CATIONIC LIPID COMPOUNDS | PURDY, KYLE A | — |
| 18487330 | Stable Antiemetic Emulsions for Parenteral Administration | MOU, LIYUAN | — |
| 18341470 | MODULAR FENCE SYSTEM | HALL, ZACHARY A | — |
| 18183656 | FIREARM SUPPRESSOR WITH SECONDARY RETENTION SYSTEM | KLEIN, GABRIEL J | — |
| Client (Assignee) | Pending OAs |
|---|---|
| Guangzhou Anobri Pharmaceutical Co. Ltd. | 3 |
| Stabilus GmbH | 1 |
| NEOCIS INC. | 1 |
| Opes Corporation OY | 1 |
| SLAYBACK PHARMA LLC | 1 |
| ORIGIN POINT BRANDS LLC | 1 |
| Rugged Design, Inc. | 1 |
| Art Unit | Apps |
|---|---|
| 3616 | 1 |
| 1693 | 1 |
| 1658 | 1 |
| 3658 | 1 |
| 1613 | 1 |
| 1611 | 1 |
| 1628 | 1 |
| 3678 | 1 |
| 3641 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18896412 | DAMPING APPARATUS | Stabilus GmbH | HSIAO, JAMES K | 3616 | §102§112Other | Non-Final OA | — | Pending | Sep 25, 2024 |
| 18723921 | A SYNERGISTIC PHARMACEUTICAL COMPOSITION AND ITS ANTIVIRAL USE | Guangzhou Anobri Pharmaceutical Co. Ltd. | KRISHNAN, GANAPATHY | 1693 | §103Other | Non-Final OA | — | Pending | Jun 25, 2024 |
| 18699969 | NOVEL DEUTERATED CYANO COMPOUNDS, PREPARATION METHODS, COMPOSITIONS AND APPLICATIONS | Guangzhou Anobri Pharmaceutical Co. Ltd. | NIEBAUER, RONALD T | 1658 | §103§112DP | Non-Final OA | — | Pending | Apr 10, 2024 |
| 18692460 | DENTAL IMAGING SYSTEM, AND DENTAL ROBOT SYSTEM INCLUDING SAME | Neocis Inc. | EMMETT, MADISON B | 3658 | §103 | Final Rejection | 8d | Pending | Mar 15, 2024 |
| 18692208 | ACTIVE INGREDIENT DELIVERY SYSTEM | Opes Corporation OY | CHANG, KYUNG SOOK | 1613 | §103 | Non-Final OA | 70d | Pending | Mar 14, 2024 |
| 18294314 | NOVEL CATIONIC LIPID COMPOUNDS | Guangzhou Anobri Pharmaceutical Co. Ltd. | PURDY, KYLE A | 1611 | §102§103 | Non-Final OA | — | Pending | Feb 01, 2024 |
| 18487330 | Stable Antiemetic Emulsions for Parenteral Administration | Slayback Pharma LLC | MOU, LIYUAN | 1628 | §103 | Final Rejection | — | Pending | Oct 16, 2023 |
| 18341470 | MODULAR FENCE SYSTEM | Origin Point Brands LLC | HALL, ZACHARY A | 3678 | §102 | Final Rejection | — | Pending | Jun 26, 2023 |
| 18183656 | FIREARM SUPPRESSOR WITH SECONDARY RETENTION SYSTEM | Rugged Design, Inc. | KLEIN, GABRIEL J | 3641 | §103 | Non-Final OA | — | Pending | Mar 14, 2023 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial80.4% of resolved applications prosecuted by Parker Poe Adams and Bernstein, LLP were allowed, across 238 applications in USPTO records.
4.26 office actions per allowed application on average.
9 pending office actions as of October 2026, for 7 clients, before 9 examiners in 9 art units.
